In conclusion, this study explores a ChaC1-centric pharmacological discovery platform that identifies proteasome inhibitor and auranofin combination therapy as a mechanistically rational anti-HCC strategy. The gene discussed is CHAC1; the disease is hepatocellular carcinoma.